Laboratorios Richmond S.A.C.I.F.

BASE:RICHD Stock Report

Market Cap: US$148.4m

Laboratorios RichmondC.I.F Past Earnings Performance

Past criteria checks 2/6

Laboratorios RichmondC.I.F has been growing earnings at an average annual rate of 3.3%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 37.1% per year. Laboratorios RichmondC.I.F's return on equity is 28.1%, and it has net margins of 45.7%.

Key information

3.3%

Earnings growth rate

3.3%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate37.1%
Return on equity28.1%
Net Margin45.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Laboratorios RichmondC.I.F makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BASE:RICHD Revenue, expenses and earnings (ARS Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2437,54617,16811,8750
30 Jun 2435,1655,29912,2480
31 Mar 2435,303-3,04014,3510
31 Dec 2339,028-10,85115,0110
30 Sep 2387,633-11,20734,1430
30 Jun 2376,914-5,30529,2640
31 Mar 2372,10928623,0010
31 Dec 2257,51850917,9350
30 Sep 2245,7783,05510,4660
30 Jun 2248,2793,3278,7160
31 Mar 2236,2241,8996,3250
31 Dec 2132,3661,1525,1100
30 Sep 2119,7272903,6830
30 Jun 2112,6516353,0900
31 Mar 2110,0915842,5150
31 Dec 209,3307342,2180
30 Sep 207,6804862,0110
30 Jun 206,9783191,8730
31 Mar 206,1402351,7010
31 Dec 195,3031591,5120
30 Sep 193,902-841,3390
30 Jun 193,343-2841,2560
31 Mar 193,013-4141,1610
31 Dec 182,795-3321,0650
30 Sep 182,820-3061,0640
30 Jun 182,296-1258830
31 Mar 181,904137060
31 Dec 171,591495880
30 Sep 171,0481002870
30 Jun 179881032640
31 Mar 179121062420
31 Dec 16856952140
30 Sep 16653282150
30 Jun 16568141970
31 Mar 16504121700
31 Dec 1544661540
30 Sep 15407171260
30 Jun 15384151130
31 Mar 15361121060
31 Dec 1434761040
30 Sep 1429601060
30 Jun 14273-111020
31 Mar 14259-12990
31 Dec 132600960

Quality Earnings: RICHD has a large one-off gain of ARS6.1B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: RICHD became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RICHD has become profitable over the past 5 years, growing earnings by 3.3% per year.

Accelerating Growth: RICHD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RICHD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.8%).


Return on Equity

High ROE: Whilst RICHD's Return on Equity (28.1%) is high, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies